Caladrius Biosciences Inc. (NASDAQ:CLBS)’s share price fell 2.3% on Monday . The company traded as low as $5.95 and last traded at $6.01, with a volume of 57,237 shares. The stock had previously closed at $6.15.

A number of brokerages have recently weighed in on CLBS. HC Wainwright restated a “buy” rating on shares of Caladrius Biosciences in a research note on Wednesday, August 10th. Zacks Investment Research upgraded Caladrius Biosciences from a “hold” rating to a “strong-buy” rating and set a $6.75 target price on the stock in a research note on Tuesday, August 2nd. Maxim Group reiterated a “hold” rating on shares of Caladrius Biosciences in a research note on Friday, May 6th. Finally, Rodman & Renshaw upgraded Caladrius Biosciences to a “buy” rating in a research note on Saturday, April 30th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Caladrius Biosciences presently has an average rating of “Buy” and a consensus price target of $4.20.

The company’s 50-day moving average is $5.76 and its 200-day moving average is $6.17. The stock’s market cap is $35.54 million.

Caladrius Biosciences (NASDAQ:CLBS) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($1.33) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.75) by $0.42. The company earned $8.30 million during the quarter, compared to analysts’ expectations of $7.53 million. Analysts expect that Caladrius Biosciences Inc. will post ($4.54) EPS for the current year.

In other Caladrius Biosciences news, Director Eric Wei sold 87,500 shares of the firm’s stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $0.60, for a total transaction of $52,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Caladrius Biosciences, Inc, formerly NeoStem, Inc, is a clinical-stage biopharmaceutical company. The Company’s clinical program is based on its dendritic cell and cancer cell technology. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis, known as cancer or tumor initiating cells (CSCs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.